William Frank Iv Hulse Sells 81,446 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at $3,859,237.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG traded down $0.02 during mid-day trading on Wednesday, reaching $8.10. 670,387 shares of the company’s stock were exchanged, compared to its average volume of 709,348. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.97. The firm has a 50-day moving average price of $8.51 and a two-hundred day moving average price of $7.80. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

Institutional Trading of MiMedx Group

Several hedge funds have recently made changes to their positions in the company. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group during the 4th quarter worth $28,000. Virtus Fund Advisers LLC purchased a new stake in MiMedx Group during the fourth quarter valued at about $35,000. Van ECK Associates Corp bought a new position in MiMedx Group during the fourth quarter worth about $40,000. Tower Research Capital LLC TRC increased its stake in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after purchasing an additional 2,837 shares in the last quarter. Finally, Point72 DIFC Ltd raised its position in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares during the period. 79.15% of the stock is currently owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.